DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: NSCLC
Non-small Cell Lung Cancer
Lung Cancer

Interventions: Radiation: Stereotactic boost
Radiation: Conventional RT
Drug: Etoposide
Drug: Cisplatin

First Posted Date: 2010-10-18

Last Posted Date: 2015-06-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 1

Registration Number: NCT01222572

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study

Phase 2

Terminated

Conditions: Squamous Cell Carcinoma of the Head and Neck
Human Papilloma Virus

Interventions: Drug: docetaxel
Drug: cisplatin
Drug: 5-FU
Radiation: IMRT
Drug: cetuximab
Drug: carboplatin

First Posted Date: 2010-10-15

Last Posted Date: 2017-12-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 7

Registration Number: NCT01221753

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease

Completed

Conditions: Chronic Graft vs Host Disease
cGVHD
Graft vs Host Disease

First Posted Date: 2010-10-15

Last Posted Date: 2015-03-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT01221766

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

Phase 2

Completed

Conditions: Ocular Melanoma

Interventions: Drug: STA-9090

First Posted Date: 2010-09-13

Last Posted Date: 2018-10-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 17

Registration Number: NCT01200238

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

Phase 2

Active, not recruiting

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: bevacizumab
Drug: trastuzumab
Drug: oxaliplatin
Drug: capecitabine

First Posted Date: 2010-08-31

Last Posted Date: 2024-10-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 37

Registration Number: NCT01191697

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Trastuzumab and Vinorelbine in Advanced Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer
Metastatic Breast Cancer

Interventions: Drug: trastuzumab
Drug: vinorelbine

First Posted Date: 2010-08-20

Last Posted Date: 2019-01-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 31

Registration Number: NCT01185509

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

Phase 1

Completed

Conditions: Solid Tumor
Kidney Cancer

Interventions: Drug: pazopanib
Drug: everolimus

First Posted Date: 2010-08-18

Last Posted Date: 2019-10-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT01184326

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders

Active, not recruiting

Conditions: Waldenstrom's Macroglobulinemia
Multiple Myeloma
Smoldering Multiple Myeloma
Lymphoblastic Lymphoma

First Posted Date: 2010-08-09

Last Posted Date: 2025-03-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 656

Registration Number: NCT01177527

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Methylphenidate for Cancer-Related Fatigue

Phase 1

Terminated

Conditions: Cancer

Interventions: Drug: methylphenidate
Other: Placebo

First Posted Date: 2010-07-19

Last Posted Date: 2019-04-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 3

Registration Number: NCT01164956

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Phase 1

Terminated

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Everolimus
Drug: Rituximab
Drug: Bortezomib

First Posted Date: 2010-05-18

Last Posted Date: 2021-04-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 46

Registration Number: NCT01125293

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy